Log in

Tracker

Reverse split, Nasdaq notice and delisting tracker

Reverse stock splits, Nasdaq and NYSE deficiency notices, regained compliance, delistings and new listings at public biotech companies, newest first.

Updated October 31, 2026. 538 entries. Download as CSV. Free to cite with a link to this page. All trackers.

DateCompanyTypeWhat happened
Propanc Biopharma PPCBReverse splitPropanc Biopharma faces Nasdaq delisting on bid price, plans to appeal
Reviva Pharmaceuticals Holdings RVPHReverse splitReviva asks stockholders to approve reverse split of up to 1-for-100
Glucotrack GCTKDelistingNasdaq to delist Glucotrack shares after bid price exception ends
Milestone Pharmaceuticals MISTListing changeMilestone Pharmaceuticals falls below Nasdaq's $1.00 minimum bid rule
OSR Health OSRHDelistingNasdaq panel delists OSR Health over $1.00 bid price rule
aTyr Pharma ATYRReverse splitaTyr Pharma sets 1-for-40 reverse split, shares trade adjusted from October 29
CDT Equity CDTReverse splitCDT Equity seeks votes on reverse splits up to 1-for-1,000 and Astor note shares
Enlivex ENLVReverse splitEnlivex gets Nasdaq delisting notice, plans appeal and 1-for-16 reverse split
GeoVax Labs GOVXListing changeGeoVax signs $1,000,000 credit line as five directors make way for lender nominees
GeoVax Labs GOVXReverse splitGeoVax stockholders approve reverse split of up to 1-for-25 and warrant share issuance
Pulmatrix PULMReverse splitPulmatrix stockholders approve Eos SENOLYTIX merger and a reverse split
AEON Biopharma AEONReverse splitAEON Biopharma seeks approval for a reverse split of up to 1-for-100
Oncopeptides AB ONCOReverse splitOnconetix sets a 1-for-10 reverse stock split for November 6
Skye Bioscience SKYEReverse splitSkye Bioscience files preliminary proxy for its Redx Pharma acquisition
Silexion Therapeutics SLXNReverse splitSilexion shareholders back a 1-for-24 reverse split and more authorized shares
TScan Therapeutics TCRXReverse splitTScan Therapeutics asks stockholders to approve a reverse split of up to one-for-fifty
Akebia Therapeutics AKBAReverse splitAkebia Therapeutics gets Nasdaq bid price notice, has until April 19, 2027
Citius Oncology, Citius Pharmaceuticals CTORCTXRListing changeCitius Oncology gets Nasdaq extension to April 19, 2027 on bid price
Lunai Bioworks LNAIDelistingLunai Bioworks gets Nasdaq delisting notice and plans to leave the exchange
Medicus Pharma MDCXRegained complianceMedicus Pharma regains Nasdaq $1.00 bid price compliance days after delisting letter
Nuwellis NUWEReverse splitNuwellis sets one-for-nine reverse stock split effective October 26
Azitra AZTRReverse splitAzitra to carry out 1-for-10 reverse stock split on October 26
Enlivex ENLVListing changeEnlivex announces 1-for-16 reverse share split effective October 27, 2026
Alaunos Therapeutics TCRTListing changeAlaunos Therapeutics says $350.0 million financing restores Nasdaq equity compliance
Silexion Therapeutics SLXNReverse splitSilexion adjourns vote on 500 million new shares and reverse split to October 26
Sangamo Therapeutics SGMOQDelistingSangamo's Nasdaq delisting becomes final as Chapter 11 case continues
Mustang Bio MBIOReverse splitMustang Bio gets a second 180-day Nasdaq grace period to fix its bid price
MANNATECH INC MTEXListing changeMannatech says it regained Nasdaq stockholders' equity compliance
Immutep IMMRegained complianceImmutep Ltd regains Nasdaq bid price compliance after ADS ratio change
CytoMed Therapeutics GDTCDeficiency noticeCytoMed Therapeutics gets Nasdaq bid price notice, has until April 5, 2027
Alaunos Therapeutics TCRTDelistingAlaunos Therapeutics gets Nasdaq delisting notice under $2,500,000 stockholders' equity rule
Artelo Biosciences ARTLListing changeArtelo Biosciences flags exposure to Nasdaq's new $5,000,000 market value rule
Biodexa Pharmaceuticals BDRXListing changeBiodexa changes ADS ratio to 400 ordinary shares, a one-for-eight reverse ADS split
Boundless Bio BOLDReverse splitBoundless Bio files S-4 for Serapha merger; partner later reports early SERP-01 data
NEXGEL, INC. NXGLReverse splitNexGel sets a 1-for-20 reverse stock split effective October 12, 2026
Aditxt ADTXDelistingNasdaq files to remove Aditxt common stock from listing
Redhill Biopharma RDHLListing changeRedhill Biopharma gets 180 more days on Nasdaq bid price, to April 5, 2027
Sangamo Therapeutics SGMOQDelistingNasdaq files SEC notice to remove Sangamo Therapeutics stock from listing
VivoSim Labs, INC. VIVSReverse splitVivoSim Labs stockholders elect two directors and approve split range
Kyntra Bio KYNBDelistingKyntra Bio gets Nasdaq delisting determination, requests a hearing
Universe Pharmaceuticals UPCDeficiency noticeUniverse Pharmaceuticals holders approve conditional 10-into-1 share consolidation
BeyondSpring BYSIDeficiency noticeBeyondSpring gets Nasdaq notice after market value falls below $35 million
Dare Bioscience DAREReverse splitDaré Bioscience gets Nasdaq notice for stock below $1.00
Lantern Pharma LTRNDeficiency noticeLantern Pharma gets Nasdaq notice over $35,000,000 market value rule
Nutriband NTRBDelistingNasdaq files removal notice as Nutriband public warrants expire
Abpro Holdings ABPODelistingNasdaq files to remove Abpro Holdings stock and warrants from listing
Clearmind Medicine CMNDListing changeClearmind Medicine to effect 1-for-8 reverse share split, trading from October 5, 2026
Evogene EVGNReverse splitEvogene gets extra 180 days from Nasdaq to fix bid price, to March 29, 2027
SciSparc SPRCListing changeSciSparc reports $4,436 thousand in cash and $6,051 thousand loss for first half
Tevogen TVGNRegained complianceTevogen regains compliance with Nasdaq Global Market listing rules
Lakewood-Amedex Biotherapeutics LABTReverse splitLakewood-Amedex holders approve share increase and reverse split authority
Liminatus Pharma LIMNReverse splitLiminatus Pharma regains Nasdaq compliance after 1-for-50 reverse split
Gossamer Bio GOSSReverse splitGossamer Bio regains Nasdaq minimum bid price compliance
Polyrizon PLRZListing changePolyrizon reports $8,410 thousand in cash at June 30, 2026
CDT Equity CDTReverse splitCDT Equity to do 1-for-25 reverse stock split on Nasdaq
Calidi Biotherapeutics CLDIDeficiency noticeCalidi Biotherapeutics receives NYSE American equity deficiency notice
Matinas Biopharma Holdings MTNBReverse splitMatinas Biopharma effects one-for-fifteen reverse stock split
Silexion Therapeutics SLXNDelistingSilexion adds bid-price deficiency to pending Nasdaq panel review
Outlook Therapeutics OTLKDeficiency noticeOutlook Therapeutics gets a Nasdaq bid-price notice weeks after its drug's approval
BGM Group BGMListing changeBGM Group announces 30-for-1 share consolidation, trading from October 1, 2026
Xenetic Biosciences XBIOReverse splitXenetic files investor presentation on proposed transaction with Santersus
Jaguar Health JAGXReverse splitJaguar Health completes 1-for-15 reverse split and removes old preferred series
Scinai Immunotherapeutics SCNIRegained complianceScinai Immunotherapeutics regains Nasdaq bid price compliance
InMed Pharmaceuticals INMDeficiency noticeInMed receives Nasdaq notice on minimum shareholders' equity
Moleculin Biotech MBRXReverse splitMoleculin Biotech gets Nasdaq staff determination on bid price, plans hearing request
BeyondSpring BYSIDeficiency noticeBeyondSpring gets Nasdaq minimum bid price notice, has until March 16, 2027
Filana Therapeutics FLNADeficiency noticeFilana Therapeutics gets Nasdaq bid price notice, has until March 16, 2027
Soligenix SNGXReverse splitSoligenix stockholders approve reverse split authority and share increase
Aditxt ADTXDelistingNasdaq to delist Aditxt common stock after June suspension
Pasithea Therapeutics KTTAListing changePasithea warrants to expire on September 17, 2026
Matinas Biopharma Holdings MTNBReverse splitMatinas BioPharma sets one-for-fifteen reverse stock split
Bone Biologics BBLGReverse splitBone Biologics gets Nasdaq minimum bid price notice, has until March 9, 2027
iSpecimen ISPCListing changeiSpecimen gets until November 25, 2026 to meet Nasdaq equity rule
Can-Fite BioPharma CANFReverse splitCan-Fite details 1-for-3,000 reverse split and ADS ratio change in 6-K
iSpecimen ISPCListing changeiSpecimen agrees to buy Foldlab AI software assets for $4,500,000
Matinas Biopharma Holdings MTNBDeficiency noticeMatinas BioPharma receives NYSE American stockholders' equity notice
IRulya Therapeutics, IRulya Therapeutics IRLAQNCXDeficiency noticeQuince Therapeutics (now IRulya Therapeutics) gets Nasdaq stockholders' equity deficiency notice
XORTX Therapeutics XRTXListing changeXORTX Therapeutics files $2,500,000 paid promotion agreement with IR Agency
PRF Technologies PRFXListing changePRF Technologies reports $8,526 thousand in cash at June 30, 2026
BioRestorative Therapies BRTXReverse splitBioRestorative gets Nasdaq late-filing notice, then does a 1-for-20 reverse split
Anavex Life Sciences AVXLRegained complianceAnavex regains Nasdaq compliance after filing overdue 10-Qs on August 28, 2026
Quantum Biopharma QNTMDelistingQuantum BioPharma applies to delist Class B shares from the CSE
Earth Science Tech ETSTReverse splitEarth Science Tech holders approve reverse split authority for uplisting
Oragenics OGENDeficiency noticeOragenics receives NYSE American deficiency letter on equity
Glucotrack GCTKReverse splitGlucotrack effects 1-for-15 reverse stock split
ENvue Medical FEEDReverse splitENvue Medical announces 1-for-12 reverse stock split effective September 1
Shuttle Pharmaceuticals Holdings SHPHDeficiency noticeShuttle Pharmaceuticals gets Nasdaq deficiency notice over late Form 10-Q
China SXT Pharmaceuticals SXTCListing changeChina SXT cuts pre-paid share purchase floor price back to $0.20 from $16.00
OSR Health OSRHDeficiency noticeOSR Health hearing before Nasdaq Panel set for September 29
Artelo Biosciences ARTLReverse splitArtelo Biosciences sets 1-for-9 reverse split, trading from August 31, 2026
Valion Bio VBIOReverse splitValion sets 1-for-25 reverse stock split to regain Nasdaq compliance
Korsana Biosciences KRSAReverse splitCyclerion (now Korsana Biosciences) shareholders approve merger issuance and 1-for-7 reverse split
Senti Biosciences Holdings SNTIDeficiency noticeSenti Biosciences gets two Nasdaq notices, on bid price and a $3.4M equity deficit
INTERPACE BIOSCIENCES, INC. IDXGReverse splitInterpace Biosciences sets 1-for-5 reverse stock split to support Nasdaq bid
Ensysce Biosciences ENSCListing changeEnsysce gets Nasdaq bid price extension to February 2027
Longeveron LGVNReverse splitLongeveron does a 1-for-10 reverse split to meet Nasdaq's $1 bid minimum
VivoSim Labs, INC. VIVSReverse splitVivoSim Labs receives Nasdaq bid price notice with February 2027 deadline
Pasithea Therapeutics KTTAListing changePasithea receives Nasdaq extension to regain bid price compliance
Azitra AZTRRegained complianceAzitra regains NYSE American continued listing compliance
Kairos Pharma KAPAReverse splitKairos Pharma sets 1-for-7 reverse stock split effective September 1, 2026
Estrella Immunopharma ESLADeficiency noticeEstrella Immunopharma gets Nasdaq minimum bid price notice, has until February 16, 2027 to comply
Adial Pharmaceuticals ADILDeficiency noticeAdial Pharmaceuticals gets Nasdaq stockholders' equity notice, plan due October 2, 2026
Citius Pharmaceuticals, Citius Oncology CTXRCTORListing changeCitius Pharmaceuticals gets Nasdaq extension to February 8, 2027 on bid price
Profusa PFSAListing changeProfusa reports Q2 2026 results and progress on G3 option
Curanex Pharmaceuticals CURXReverse splitCuranex regains Nasdaq bid-price compliance after 1-for-20 reverse split
OSR Health OSRHDelistingOSR Health receives Nasdaq delisting determination, will request hearing
Mereo BioPharma Group MREOListing changeMereo BioPharma gets second Nasdaq bid price period, to February 16, 2027
Skye Bioscience SKYEDeficiency noticeSkye Bioscience gets Nasdaq notice: stockholders' equity was ($497,307)
BullFrog AI Holdings BFRGReverse splitBullFrog AI granted Nasdaq second compliance period for bid price
Liminatus Pharma LIMNReverse splitLiminatus Pharma sets 1-for-50 reverse stock split to meet Nasdaq minimum bid price requirement
Lexaria Bioscience LEXXRegained complianceLexaria Bioscience regains Nasdaq bid price compliance, hearing cancelled
XORTX Therapeutics XRTXListing changeXORTX reports $994,045 in cash and a going-concern note for first half of 2026
Adagio Medical Holdings ADGMDeficiency noticeAdagio Medical receives Nasdaq notice on stockholders' equity
Silexion Therapeutics SLXNDelistingSilexion had $2.2 million in cash at June 30 and flags going-concern doubt
CASI Pharmaceuticals CASIFDelistingCASI Pharmaceuticals reports $3.8 million cash, details Nasdaq delisting and OTCQB quote
Skye Bioscience SKYEListing changeSkye Bioscience outlines Redx Pharma deal in August 14, 2026 investor deck
Satellos Bioscience MSCLListing changeSatellos reports $47,251 thousand net equity proceeds in first half of 2026
Eloxx Pharmaceuticals ELOXNew listingEloxx reports second-quarter results after a $66.0 million offering and Nasdaq uplisting
Lakewood-Amedex Biotherapeutics LABTReverse splitLakewood-Amedex Biotherapeutics sets vote on share increase to 100,000,000 and reverse split
Wave Life Sciences WVEDelistingWave Life Sciences Ltd. (now Wave Life Sciences, Inc.) files Form 15 to end SEC reporting
Niki BioSolutions NIKIRegained complianceAptorum Group (now Niki BioSolutions) regains Nasdaq bid price compliance
Zhengye Biotechnology Holding ZYBTRegained complianceZhengye Biotechnology regains Nasdaq bid price compliance
Genprex GNPXRegained complianceGenprex regains Nasdaq bid price compliance, panel oversight runs to December 7
Vistagen Therapeutics VTGNListing changeVistagen gets 180-day Nasdaq extension, until February 1, 2027, on minimum bid price rule
Aura Biosciences AURAListing changeAura Biosciences holders approve raising authorized shares to 500,000,000
AEON Biopharma AEONRegained complianceAEON regains NYSE American compliance after July offering
AETHLON MEDICAL INC AEMDReverse splitAethlon effects 1-for-5 reverse stock split effective July 31
MIRA Pharmaceuticals MIRADeficiency noticeMira Pharmaceuticals gets Nasdaq bid price deficiency notice; deadline is January 25, 2027
PDS Biotechnology PDSBReverse splitPDS Biotechnology gets Nasdaq minimum bid price deficiency letter, has until January 26, 2027
Evogene EVGNReverse splitEvogene calls September 4 meeting on director slates, share capital and reverse split
Genprex GNPXDeficiency noticeNasdaq panel grants Genprex an exception on the $1.00 bid price rule
Alterity Therapeutics ATHListing changeAlterity reports A$37.3 million cash after 1-for-50 share consolidation
Lexaria Bioscience LEXXReverse splitLexaria sets 1-for-15 reverse split for August 3, 2026 to meet Nasdaq bid rule
Traws Pharma TRAWDeficiency noticeTraws Pharma receives Nasdaq notice on $1.00 minimum bid price
Celularity CELUDeficiency noticeCelularity gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027 to comply
Earth Science Tech ETSTReverse splitEarth Science Tech to ask holders for advisory vote on reverse split for uplisting
BGM Group BGMRegained complianceBGM Group regains Nasdaq compliance after filing its late 20-F
Calidi Biotherapeutics CLDIReverse splitCalidi Biotherapeutics effects 1-for-16 reverse stock split
VivoSim Labs, INC. VIVSDeficiency noticeVivoSim Labs gets Nasdaq equity notice and cites July warrant exercises
Apimeds Pharmaceuticals US APUSReverse splitApimeds Pharmaceuticals reverse stock split took effect July 24
Labiana Health SA LABDeficiency noticeStandard BioTools gets Nasdaq minimum bid price notice, has until January 19, 2027
Oncolytics Biotech ONCYDeficiency noticeOncolytics Biotech gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027
FibroBiologics FBLGReverse splitFibroBiologics gets Nasdaq delisting determination over $1.00 minimum bid price, plans appeal
XTL Biopharmaceuticals XTLBRegained complianceXTL Biopharmaceuticals regains Nasdaq compliance, faces one-year panel monitor
Rockwell Medical RMTIRegained complianceRockwell Medical regains Nasdaq bid price compliance, matter closed
Dare Bioscience DAREDelistingDaré Bioscience gets Nasdaq notice on stockholders' equity, plans hearing
CDT Equity CDTReverse splitCDT Equity to do 1-for-10 reverse stock split effective July 17
Genprex GNPXReverse splitGenprex plans a 1-for-22 reverse stock split effective July 16
Apollomics APLMRegained complianceApollomics regains Nasdaq compliance on $35 million market value rule
Apimeds Pharmaceuticals US APUSReverse splitApimeds Pharmaceuticals sets reverse split date of July 24
ENDRA Life Sciences NDRARegained complianceENDRA regains Nasdaq stockholders' equity compliance
AquaBounty Technologies AQBReverse splitAquaBounty's board declines reverse stock split for now
Oragenics OGENReverse splitOragenics names John Spencer CFO and reports annual meeting votes
FOXO TECHNOLOGIES INC. FOXOReverse splitFOXO CEO gives mid-year 2026 update and says uplisting is under consideration
COSCIENS Biopharma CSCIDelistingCOSCIENS Biopharma files Form 15 to end SEC reporting duties
Gelteq GELSListing changeGelteq closes second debt tranche, receiving $2.5 million net of discount
FOXO TECHNOLOGIES INC. FOXOReverse splitFOXO completes 1-for-3,000 reverse stock split
HCW Biologics HCWBReverse splitHCW Biologics regains Nasdaq bid price compliance, faces monitor until June 17, 2027
Rockwell Medical RMTIReverse splitRockwell Medical sets 1-for-10 reverse stock split for July 1, 2026
Matinas Biopharma Holdings MTNBDeficiency noticeMatinas BioPharma receives NYSE American equity notice, plan accepted
Nuwellis NUWEReverse splitNuwellis to effect one-for-thirty-five reverse stock split on June 25
Akebia Therapeutics AKBAListing changeAkebia stockholders approve raising authorized common shares to 500,000,000
Allogene Therapeutics ALLOListing changeAllogene holders approve 800,000,000 shares; files ATM supplement for up to $135.0 million
CytomX Therapeutics CTMXListing changeCytomX holders approve 600,000,000 authorized shares and larger equity plans
Eledon Pharmaceuticals ELDNListing changeEledon holders approve raising authorized common shares to 450,000,000
Provectus Biopharmaceuticals PVCTReverse splitProvectus holders authorize reverse split of between 1-for-10 and 1-for-50
Silo Pharma SILORegained complianceSilo Pharma regains Nasdaq minimum bid price compliance
Dyadic International DYAIDelistingDyadic International gets Nasdaq delisting notice over bid price, plans hearing
Xencor XNCRListing changeXencor holders approve 4,000,000-share increase to 2023 equity plan
Lakewood-Amedex Biotherapeutics LABTReverse splitLakewood-Amedex Biotherapeutics sets 1-for-10 reverse split, trading June 22, 2026
AIM ImmunoTech AIMRegained complianceAIM ImmunoTech regains NYSE American stockholders' equity compliance
Rockwell Medical RMTIReverse splitRockwell Medical holders approve reverse stock split amendment
Adagio Medical Holdings ADGMDeficiency noticeAdagio Medical gets Nasdaq bid price notice, has until December 9
Genprex GNPXReverse splitNasdaq staff says Genprex is not eligible for a bid price compliance period
Soligenix SNGXDeficiency noticeSoligenix gets Nasdaq minimum bid price notice, ends HyBryte program
BioCardia BCDAListing changeBioCardia believes it regained Nasdaq stockholders' equity compliance after at-the-market sales
Celularity CELUDelistingCelularity gets Nasdaq notice on market value of listed securities, has until December 7, 2026
Annexon ANNXListing changeAnnexon holders approve raising authorized common shares to 500,000,000
Cuprina Holdings (Cayman) CUPRRegained complianceCuprina Holdings regains Nasdaq compliance, July 7, 2026 hearing cancelled
Niki BioSolutions NIKIListing changeAptorum Group (now Niki BioSolutions) shareholders approve DiamiR merger
Solid Biosciences SLDBListing changeSolid Biosciences holders approve doubling authorized shares to 480,000,000
Voyager Therapeutics VYGRListing changeVoyager Therapeutics holders approve doubling common stock to 240,000,000 shares
Bluejay Diagnostics BJDXReverse splitBluejay stockholders approve reverse split authority
Jasper Therapeutics JSPRReverse splitJasper Therapeutics receives Nasdaq minimum bid price notice, has until November 30, 2026
Relay Therapeutics RLAYListing changeRelay Therapeutics holders approve raising authorized shares to 450,000,000
MetaVia MTVAReverse splitMetaVia shareholders approve reverse split range of 1-for-5 to 1-for-22
aTyr Pharma ATYRReverse splitaTyr Pharma gets 180 more days from Nasdaq to meet $1.00 minimum bid price
Savara SVRAListing changeSavara holders approve doubling authorized shares to 600,000,000
OnKure Therapeutics OKURListing changeOnKure Therapeutics holders approve equity plan adding 3,231,638 shares
Trevi Therapeutics TRVIListing changeTrevi Therapeutics holders approve doubling authorized shares to 400,000,000
Silo Pharma SILOReverse splitSilo Pharma completes 1-for-15 reverse stock split
Enveric Biosciences ENVBReverse splitEnveric stockholders vote on reverse split range and larger authorized share count
Abpro Holdings ABPODelistingNasdaq council upholds Abpro Holdings delisting; OTC Pink quotation expected
CDT Equity CDTDeficiency noticeCDT Equity gets Nasdaq notice over late first-quarter 10-Q
Silexion Therapeutics SLXNReverse splitSilexion completes 1-for-10 reverse split, its third since late 2024
Aditxt ADTXDeficiency noticeNasdaq letter says Aditxt falls below $2,500,000 equity minimum
Dermata Therapeutics DRMAListing changeDermata shareholders approve warrant repricing and larger equity plan
Sintofarm SA Bucuresti SINTDeficiency noticeSINTX Technologies gets Nasdaq stockholders' equity deficiency notice, plan due July 6, 2026
Bio-Path Holdings BPTHReverse splitBio-Path cancels planned reverse split and approves treasury plan
Ensysce Biosciences ENSCDelistingEnsysce receives Nasdaq notice on stockholders' equity requirement
FOXO TECHNOLOGIES INC. FOXOReverse splitFOXO settles J.H. Darbie fees and seeks a reverse stock split
TransCode Therapeutics RNAZDeficiency noticeTransCode Therapeutics gets Nasdaq stockholders' equity deficiency notice
Tempest Therapeutics TPSTDeficiency noticeTempest Therapeutics gets Nasdaq notice on stockholders' equity, flags board independence gap
Oncopeptides AB ONCOReverse splitOnconetix to effect 1-for-10 reverse stock split on May 21, 2026
Clearmind Medicine CMNDReverse splitClearmind Medicine announces 1-for-10 reverse split, effective May 21, 2026
Larimar Therapeutics LRMRListing changeLarimar Therapeutics holders approve raising authorized shares to 215,000,000
Palatin Technologies PTNListing changePalatin Technologies to move stock listing from NYSE American to Nasdaq Capital Market
NervGen Pharma NGENListing changeNervGen reports $16.6 million cash and investments after Nasdaq listing
Skye Bioscience SKYEDeficiency noticeSkye Bioscience gets Nasdaq notice: stockholders' equity of $9,011,804 is below $10,000,000 minimum
Rani Therapeutics Holdings RANIDeficiency noticeRani Therapeutics gets Nasdaq minimum bid price notice, CFO Svai Sanford to resign
Enlivex ENLVDeficiency noticeEnlivex gets Nasdaq bid price notice, has until November 9, 2026
Aditxt ADTXReverse splitAditxt plans 1-for-27 reverse stock split effective May 18
Bio Green Med Solution BGMSListing changePreferred stock removed from Nasdaq as Bio Green Med reports first-quarter results
Cuprina Holdings (Cayman) CUPRListing changeCuprina shareholders approve share consolidation and higher Class B voting rights
LogicMark LGMKListing changeLogicMark revenue rises 24% in first quarter 2026
PureTech Health PRTCDelistingPureTech Health PLC files Form 25 to delist its ADSs from Nasdaq
SciSparc SPRCDelistingSciSparc gets conditional Nasdaq compliance letter on stockholders' equity
iSpecimen ISPCListing changeiSpecimen prices $2.5 million private placement at $5.12 per share
Humacyte HUMADeficiency noticeHumacyte gets Nasdaq minimum bid price deficiency notice, has until November 2, 2026
Enveric Biosciences ENVBReverse splitEnveric corrects reverse split maximum in proxy materials to 1-for-15
Rockwell Medical RMTIReverse splitRockwell Medical to put reverse stock split to a vote at June 12, 2026 meeting
CorMedix CRMDListing changeCorMedix asks holders to ratify past changes to preferred stock terms
PureTech Health PRTCDelistingPureTech to delist ADSs from Nasdaq and keep its primary London listing
Citius Oncology CTORDeficiency noticeCitius Oncology gets Nasdaq minimum bid price deficiency notice, has until October 19, 2026
InflaRx IFRXRegained complianceInflaRx regains Nasdaq bid price compliance
iSpecimen ISPCReverse splitiSpecimen plans 1-for-40 reverse stock split effective April 27, 2026
Tevogen TVGNDeficiency noticeTevogen Bio Holdings (now Tevogen Inc.) gets two Nasdaq deficiency notices on market value
Apimeds Pharmaceuticals US APUSDeficiency noticeApimeds Pharmaceuticals gets NYSE American late filing notice for 2025 Form 10-K
Cue Biopharma CUEReverse splitCue Biopharma sets 1-for-30 reverse stock split for April 23, 2026
Altimmune ALTListing changeAltimmune holders approve doubling authorized shares to 400,000,000
Mustang Bio MBIODeficiency noticeMustang Bio receives Nasdaq bid price deficiency notice
Cue Biopharma CUEReverse splitCue Biopharma holders approve reverse split range of 1-for-30 to 1-for-50
Alaunos Therapeutics TCRTDeficiency noticeAlaunos receives Nasdaq notice on stockholders' equity requirement
Kyntra Bio KYNBDeficiency noticeKyntra Bio gets Nasdaq deficiency notice on $50 million total assets and revenue rule
Gossamer Bio GOSSDeficiency noticeGossamer Bio receives Nasdaq minimum bid price deficiency notice, has until October 5, 2026
Artelo Biosciences ARTLRegained complianceArtelo regains Nasdaq listing compliance, under one-year panel monitor
Matinas Biopharma Holdings MTNBDeficiency noticeMatinas BioPharma receives NYSE American notice on three equity standards
AEON Biopharma AEONDeficiency noticeAEON Biopharma receives additional NYSE American notice over stockholders' equity
InMed Pharmaceuticals INMDeficiency noticeInMed Pharmaceuticals gets Nasdaq minimum bid price deficiency notice
Dyadic International DYAIDeficiency noticeDyadic International gets Nasdaq deficiency notice under Rule 5550(b) minimum listing requirements
Kazia Therapeutics KZIAListing changeKazia reports AUD 69.46 million cash after US$46.51 million PIPE in half-year report
Zivo Bioscience ZIVODelistingZIVO Bioscience to delist from OTC markets and file Form 15 to end SEC reporting
Quantum Biopharma QNTMListing changeQuantum Biopharma reports 2025 results, believes cash lasts past January 2028
Zhengye Biotechnology Holding ZYBTListing changeZhengye Biotechnology shareholders approve share reclassification and consolidation
Ernexa Therapeutics ERNAReverse splitErnexa Therapeutics gets Nasdaq minimum bid price notice, plans to request hearing
XTL Biopharmaceuticals XTLBListing changeXTL Biopharmaceuticals to change ADS ratio to 400 ordinary shares on March 25, 2026
Skye Bioscience SKYEDeficiency noticeSkye Bioscience gets Nasdaq bid price deficiency notice, has until September 14, 2026
Chemomab Therapeutics CMMBListing changeChemomab reports 2025 results, cites FDA alignment and partner talks
Biodexa Pharmaceuticals BDRXListing changeBiodexa to change ADR ratio to 500,000 shares, a one-for-five reverse ADR split
Purple Biotech PPBTRegained compliancePurple Biotech regains Nasdaq minimum bid price compliance
Yarrow Bioscience YARWListing changeVYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq bid price extension to Sept. 7, 2026
Longeveron LGVNListing changeLongeveron tells Nasdaq it lacks audit committee financial expert after director Kender resigns
Anebulo Pharmaceuticals ANEBDelistingAnebulo Pharmaceuticals files Form 15 to end SEC reporting duties
Jupiter Neurosciences JUNSDeficiency noticeJupiter Neurosciences gets two Nasdaq notices on minimum bid price and market value
Indaptus Therapeutics INDPReverse splitIndaptus stockholders approve preferred stock conversion and reverse split range
Altamira Therapeutics CYTOFDelistingAltamira Therapeutics files Form 15 to end SEC reporting duties
Regentis Biomaterials RGNTListing changeRegentis Biomaterials discloses going concern qualification in 2025 audit opinion
Psyence Biomedical PBMListing changePsyence Biomedical shareholders approve share consolidation of up to 250:1
Outlook Therapeutics OTLKDeficiency noticeOutlook Therapeutics gets Nasdaq minimum bid price deficiency notice, has until August 17, 2026
Atossa Therapeutics ATOSRegained complianceAtossa Therapeutics regains Nasdaq minimum bid price compliance
Mereo BioPharma Group MREODeficiency noticeMereo BioPharma gets Nasdaq minimum bid price deficiency notice on its ADSs
Anebulo Pharmaceuticals ANEBDelistingAnebulo Pharmaceuticals files Form 25 to withdraw its stock from Nasdaq
Citius Pharmaceuticals CTXRDeficiency noticeCitius Pharmaceuticals gets Nasdaq minimum bid price notice; compliance deadline is August 10, 2026
Lunai Bioworks LNAIReverse splitLunai Bioworks receives Nasdaq delisting determination over minimum bid price, requests hearing
Vistagen Therapeutics VTGNDeficiency noticeVistagen gets Nasdaq minimum bid price deficiency notice, with until August 3, 2026 to comply
Anebulo Pharmaceuticals ANEBDelistingAnebulo Pharmaceuticals to delist from Nasdaq and deregister with the SEC
Polaryx Therapeutics PLYXNew listingPolaryx begins Nasdaq trading through a direct listing
Tenaya Therapeutics TNYADeficiency noticeTenaya Therapeutics gets Nasdaq minimum bid price notice, has until July 27, 2026
UMeWorld UMEWNew listingUMeWorld begins trading on OTC Markets as UMEW after move to Delaware
GRI Bio GRIDeficiency noticeGRI Bio says Nasdaq found it conditionally regained stockholders' equity compliance
NRX Pharmaceuticals NRXPDeficiency noticeNRX Pharmaceuticals gets Nasdaq notice for missing annual meeting deadline
Polaryx Therapeutics PLYXReverse splitPolaryx completes one-for-four reverse stock split ahead of Nasdaq listing
Propanc Biopharma PPCBDeficiency noticePropanc Biopharma gets Nasdaq minimum bid price deficiency notice, has until June 30, 2026
Immunic IMUXReverse splitImmunic gets extra 180 days on Nasdaq bid price rule after transfer to Capital Market
Decoy Therapeutics DCOYDelistingSalarius Pharmaceuticals (now Decoy Therapeutics) gets Nasdaq delisting notice, will appeal
FibroBiologics FBLGReverse splitFibroBiologics gets Nasdaq delisting notice over bid price, plans to request a hearing
Helus Pharma HELPDelistingCybin Inc. (now Helus Pharma) files Form 25 to leave NYSE American
Northwest Biotherapeutics NWBOListing changeNorthwest Biotherapeutics holders approve raising authorized shares to 2,600,000,000
Silo Pharma SILOReverse splitSilo Pharma gets second 180 days from Nasdaq to meet $1.00 minimum bid price
Anebulo Pharmaceuticals ANEBReverse splitAnebulo drops reverse split plan for $3.50-a-share self tender of up to 300,000 shares
Apollomics APLMListing changeApollomics interim report shows $4,398 thousand shareholders' deficit at June 30, 2025
Azitra AZTRListing changeNYSE American accepts Azitra's stockholders' equity compliance plan, sets April 1, 2027 deadline
TherapeuticsMD TXMDListing changeTherapeuticsMD holders approve raising authorized common stock to 640,000,000 shares
PharmaCyte Biotech PMCBReverse splitPharmaCyte Biotech gets Nasdaq minimum bid price deficiency notice, has until June 1, 2026
Intensity Therapeutics INTSReverse splitIntensity Therapeutics gets second 180 days to meet Nasdaq minimum bid price requirement
Polyrizon PLRZListing changePolyrizon agrees to sell 552,269 shares at $9.00 in registered direct offering
GRI Bio GRIDeficiency noticeGRI Bio gets Nasdaq deficiency notice on minimum stockholders' equity requirement
GT Biopharma GTBPDeficiency noticeGT Biopharma gets Nasdaq minimum bid price notice, has until May 19, 2026 to regain compliance
Akari Therapeutics Plc AKTXDeficiency noticeAkari Therapeutics gets Nasdaq minimum bid price deficiency notice, has until May 25, 2026
MetaVia MTVAReverse splitMetaVia gets 180-day Nasdaq extension to May 26, 2026 on minimum bid price requirement
Artelo Biosciences ARTLDelistingArtelo Biosciences gets Nasdaq delisting determination over stockholders' equity, plans appeal
Moleculin Biotech MBRXDelistingMoleculin Biotech gets Nasdaq delisting determination, plans hearing panel appeal
Soligenix SNGXRegained complianceSoligenix regains Nasdaq stockholders' equity compliance after August notice
Shuttle Pharmaceuticals Holdings SHPHDelistingShuttle Pharmaceuticals believes $2.5 million private placement restored Nasdaq equity compliance
COSCIENS Biopharma CSCIDelistingCOSCIENS Biopharma, delisted from Nasdaq in September, applies for OTCQB quotation
Lunai Bioworks LNAIDeficiency noticeLunai Bioworks gets Nasdaq deficiency notice on $35 million market value requirement
Enveric Biosciences ENVBReverse splitEnveric Biosciences gets Nasdaq delisting notice, sets 1-for-12 reverse split
Oragenics OGENRegained complianceOragenics regains NYSE American equity compliance, settles Ladenburg fee claim for $700,000
Aspire-Lakewood Holdings ASBPDelistingAspire Biopharma Holdings (now Aspire-Lakewood Holdings) seeks Nasdaq hearing on delisting
HCW Biologics HCWBDeficiency noticeHCW Biologics wins Nasdaq panel extension to meet equity rule by December 31, 2025
Kura Oncology KURAListing changeKura Oncology files amended 2023 Inducement Option Plan with 3,250,000-share reserve
Adicet Bio ACETListing changeAdicet Bio gets until April 6, 2026 to meet Nasdaq bid price rule, moves listing
Decoy Therapeutics DCOYListing changeSalarius (now Decoy Therapeutics) says share sales lift equity above Nasdaq minimum
Werewolf Therapeutics HOWLListing changeWerewolf Therapeutics breaks Nasdaq audit committee rule after director dies
ZyVersa Therapeutics ZVSADelistingNasdaq files Form 25 to delist ZyVersa Therapeutics common stock
Xilio Therapeutics XLOListing changeXilio Therapeutics moves to Nasdaq Capital Market, gets until March 30, 2026 on bid price
Azitra AZTRDeficiency noticeAzitra gets NYSE American notice over minimum stockholders' equity requirement
Abpro Holdings ABPODelistingAbpro Holdings faces Nasdaq delisting after missing $1.00 bid price deadline
Azitra AZTRDeficiency noticeAzitra gets NYSE American notice over $4 million stockholders' equity standard
Xilio Therapeutics XLOListing changeXilio Therapeutics moves to Nasdaq Capital Market, gets 180 more days on $1.00 bid rule
BioCardia BCDARegained complianceBioCardia regains compliance with Nasdaq equity rule
Bon Natural Life BONListing changeBon Natural Life's interim results reflect 1-for-25 share consolidation and offering
Estrella Immunopharma ESLARegained complianceEstrella Immunopharma regains Nasdaq compliance on bid price and market value rules
Tevogen TVGNDeficiency noticeTevogen Bio Holdings Inc. (now Tevogen Inc.) gets Nasdaq minimum bid price notice
Longeveron LGVNDelistingLongeveron gets Nasdaq minimum bid price notice, has until March 23, 2026 to regain compliance
Adaptimmune Therapeutics ADAPYDelistingAdaptimmune gets Nasdaq panel exception until December 1, 2025, to fix bid price
Longeveron LGVNDeficiency noticeLongeveron gets Nasdaq notice for trading below the $1.00 minimum bid price
Silexion Therapeutics SLXNRegained complianceSilexion Therapeutics regains Nasdaq equity and bid-price compliance
BioCardia BCDAListing changeBioCardia believes it regained Nasdaq stockholders' equity compliance after stock sales
BioAtla BCABDeficiency noticeBioAtla wins Nasdaq panel extension with deadlines to fix price and equity gaps
Prelude Therapeutics PRLDRegained compliancePrelude Therapeutics regains compliance with Nasdaq $1.00 minimum bid price rule
Vaxart VXRTReverse splitVaxart to be delisted from Nasdaq after missing hearings panel conditions
ZyVersa Therapeutics ZVSADelistingNasdaq to complete delisting of ZyVersa Therapeutics stock with Form 25 filing
AquaBounty Technologies AQBRegained complianceAquaBounty regains compliance with Nasdaq $1.00 minimum bid price rule
Neuphoria Therapeutics NEUPDeficiency noticeNeuphoria Therapeutics gets Nasdaq extension to December 29, 2025 to hold annual meeting
Bio Green Med Solution BGMSListing changeBio Green Med Solution preferred stock falls short of Nasdaq $1 million value rule
Ovid Therapeutics OVIDRegained complianceOvid Therapeutics regains compliance with Nasdaq $1.00 bid price rule
Relmada Therapeutics RLMDRegained complianceRelmada Therapeutics regains compliance with Nasdaq $1.00 bid price rule
Yarrow Bioscience YARWDeficiency noticeVYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq minimum bid price notice
Pluri PLURRegained compliancePluri regains Nasdaq audit committee compliance after naming independent director
Yarrow Bioscience YARWDeficiency noticeVYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq notice for sub-$1.00 stock
OSR Health OSRHDeficiency noticeOSR Holdings (now OSR Health) gets Nasdaq notice after 30 days below $1.00
Coherus Oncology CHRSRegained complianceCoherus Oncology regains Nasdaq compliance with $1.00 minimum bid price rule
NuCana NCNAListing changeNuCana says Nasdaq confirmed compliance and closed its listing matter
CERo Therapeutics Holdings CERODelistingCERo Therapeutics appeals Nasdaq delisting over $2,500,000 stockholders' equity rule
Equillium EQRegained complianceEquillium regains compliance with Nasdaq's $1.00 minimum bid price rule
Mesoblast MSBListing changeMesoblast signs option to issue up to US$50 million of convertible notes
Adial Pharmaceuticals ADILListing changeAdial Pharmaceuticals gets 180-day Nasdaq extension on $1.00 bid price rule
Celularity CELURegained complianceCelularity regains Nasdaq compliance after filing two late quarterly reports
Ironwood Pharmaceuticals IRWDRegained complianceIronwood Pharmaceuticals regains compliance with Nasdaq $1.00 bid price rule
Context Therapeutics CNTXReverse splitContext Therapeutics gets Nasdaq extension to February 23, 2026 on minimum bid price rule
Context Therapeutics CNTXReverse splitContext Therapeutics gets 180 more days from Nasdaq to meet $1.00 bid price rule
Envoy Medical COCHDelistingEnvoy Medical asks Nasdaq panel to review delisting determination on market value rule
Enveric Biosciences ENVBDeficiency noticeEnveric Biosciences gets Nasdaq stockholders' equity deficiency notice, plan due October 10, 2025
Enveric Biosciences ENVBDeficiency noticeEnveric Biosciences falls short of Nasdaq $2,500,000 stockholders' equity rule
Century Therapeutics IPSCListing changeCentury Therapeutics gets 180 more days to meet Nasdaq bid price rule
Rallybio RLYBListing changeRallybio moves to Nasdaq Capital Market, gets 180 more days on bid price
Xilio Therapeutics XLODeficiency noticeXilio Therapeutics gets Nasdaq notice over stockholders' equity below $10.0 million
Imunon IMNNRegained complianceImunon regains compliance with Nasdaq minimum bid price requirement
Imunon IMNNRegained complianceImunon regains Nasdaq minimum bid price compliance after hearings panel confirmation
Veru VERURegained complianceVeru regains compliance with Nasdaq minimum bid price rule
BriaCell Therapeutics, BriaCell Therapeutics BCTBCTXListing changeBriaCell plans 1-for-10 share consolidation to meet Nasdaq listing rules
Cognition Therapeutics CGTXRegained complianceCognition Therapeutics regains compliance with Nasdaq $1.00 bid price rule
Cerenome CNSYListing changePlus Therapeutics (now Cerenome) wins Nasdaq equity nod, more time on $1.00 bid rule
COSCIENS Biopharma CSCIDelistingCOSCIENS Biopharma files Form 25 to withdraw its shares from Nasdaq
Liminatus Pharma LIMNDeficiency noticeLiminatus Pharma gets Nasdaq deficiency notice over late Form 10-Q
Dermata Therapeutics DRMARegained complianceDermata Therapeutics regains Nasdaq compliance after hearing panel exception
Curis CRISDelistingCuris gets Nasdaq delisting determination over market value rule, plans to appeal
Curis CRISDelistingCuris to appeal Nasdaq delisting after missing $35,000,000 market value rule
Atossa Therapeutics ATOSReverse splitAtossa Therapeutics gets 180 more days to meet Nasdaq $1.00 bid price rule
Genprex GNPXDelistingGenprex gets second Nasdaq delisting basis over stockholders' equity, requests hearing
Windtree Therapeutics WINTDelistingWindtree Therapeutics to be delisted by Nasdaq, shares move to OTC market
HCW Biologics HCWBListing changeHCW Biologics faces Nasdaq suspension over equity rule and plans to request a hearing
Genprex GNPXDelistingGenprex gets second Nasdaq deficiency notice, with equity at $1,391,195
Sol-Gel Technologies SLGLListing changeSol-Gel reports $24.2 million in cash, expects runway into early 2027
Soligenix SNGXDeficiency noticeSoligenix gets Nasdaq notice for stockholders' equity below $2,500,000
Intensity Therapeutics INTSRegained complianceIntensity Therapeutics regains Nasdaq stockholders' equity compliance
Veru VERUReverse splitVeru completes 1-for-10 reverse stock split on Nasdaq
Verrica Pharmaceuticals VRCAReverse splitVerrica Pharmaceuticals details 1-for-10 reverse split and $8.0 million Torii milestone
FibroBiologics FBLGDeficiency noticeFibroBiologics gets Nasdaq notice for market value below $35.0 million
Processa Pharmaceuticals PCSAReverse splitProcessa Pharmaceuticals gets second 180-day Nasdaq period to fix bid price
Estrella Immunopharma ESLADeficiency noticeEstrella Immunopharma gets Nasdaq deficiency notice on $35,000,000 market value requirement
Bon Natural Life BONDeficiency noticeBon Natural Life says Nasdaq closed bid price matter, with one-year panel monitor
Ocean Biomediacal OCEADelistingOcean Biomedical's Nasdaq delisting becomes final after board declines review
Exicure XCURRegained complianceExicure regains compliance with Nasdaq periodic filing rule
GeoVax Labs GOVXDeficiency noticeGeoVax receives Nasdaq bid price deficiency notice, has until January 27, 2026
iBio IBIODeficiency noticeiBio receives Nasdaq notice for trading below $1.00 minimum bid price
AIM ImmunoTech AIMReverse splitAIM ImmunoTech prices $8.0 million unit offering as it works to fix equity shortfall
Endovia Health Sciences EDVADelistingSplash Beverage Group (now Endovia Health Sciences) faces NYSE American warrant delisting
MindWalk Holdings HYFTListing changeImmunoPrecise Antibodies (now MindWalk Holdings) reports fiscal 2025 results
Ocugen OCGNRegained complianceOcugen regains compliance with Nasdaq $1.00 minimum bid price rule
Passage Bio PASGRegained compliancePassage Bio regains compliance with Nasdaq minimum bid price rule
Advanced Biomed ADVBDeficiency noticeAdvanced Biomed gets Nasdaq bid price notice, has until January 14, 2026 to comply
Neuphoria Therapeutics NEUPDeficiency noticeNeuphoria Therapeutics gets Nasdaq notice over annual meeting requirement
Avenue Therapeutics ATXIDelistingNasdaq files Form 25 to delist Avenue Therapeutics common stock
Connect Biopharma Holdings CNTBRegained complianceConnect Biopharma regains compliance with Nasdaq $1.00 minimum bid price rule
Cell Source CLCSDelistingCell Source keeps filing delayed reports after its July 2025 Form 15 notice
Indaptus Therapeutics INDPRegained complianceIndaptus Therapeutics regains Nasdaq compliance with $1.00 bid price rule
Imunon IMNNDelistingImunon gets Nasdaq Hearing Panel exception after delisting determination
Bio-Path Holdings BPTHDelistingNasdaq files Form 25 to remove Bio-Path Holdings common stock from listing
Jupiter Neurosciences JUNSRegained complianceJupiter Neurosciences regains compliance with Nasdaq $1.00 minimum bid price rule
Vor Biopharma VORListing changeVor Bio names Sandy Mahatme CFO and grants 13,882,750 inducement RSUs
Faeth Therapeutics FTHRegained complianceSensei Biotherapeutics (now Faeth Therapeutics) regains Nasdaq bid price compliance
GridAI Technologies GRDXRegained complianceEntero Therapeutics (now GridAI Technologies) regains Nasdaq annual meeting compliance
Unicycive Therapeutics UNCYReverse splitUnicycive regains Nasdaq minimum bid price compliance after reverse split
ProMIS Neurosciences PMNReverse splitProMIS Neurosciences gets second 180-day period to meet Nasdaq bid price rule
Coherus Oncology CHRSDeficiency noticeCoherus Oncology gets Nasdaq minimum bid price deficiency notice, has until December 29, 2025
Pluri PLURDeficiency noticePluri gets Nasdaq audit committee notice after director Doron Birger is not re-elected
Silo Pharma SILOReverse splitSilo Pharma gets Nasdaq minimum bid price notice, has until December 24, 2025 to regain compliance
Lexicon Pharmaceuticals LXRXReverse splitLexicon Pharmaceuticals moves to Nasdaq Capital Market to get more time on $1 bid rule
Silo Pharma SILOReverse splitSilo Pharma gets Nasdaq bid price notice, has until December 24, 2025
Pelthos Therapeutics PTHSReverse splitChannel Therapeutics (now Pelthos Therapeutics) closes merger and $50.1 million private placement
Alaunos Therapeutics TCRTListing changeAlaunos Therapeutics tells Nasdaq it falls short of audit committee rule after CEO change
Pelthos Therapeutics PTHSReverse splitChannel Therapeutics (now Pelthos) sets 10-for-one reverse split ahead of merger
Ocugen OCGNListing changeOcugen gets 180 more days from Nasdaq to meet minimum bid price, until December 29, 2025
Aptevo Therapeutics APVOListing changeAptevo says $15.9 million in new equity puts it back in line with Nasdaq rule
IN8bio INABRegained complianceIN8bio regains compliance with Nasdaq $1.00 minimum bid price rule
Immunic IMUXDeficiency noticeImmunic gets Nasdaq notice after stock falls below $1.00 for 30 days
Pasithea Therapeutics KTTADeficiency noticePasithea Therapeutics gets Nasdaq notice for trading below $1.00 bid price
Moleculin Biotech MBRXReverse splitMoleculin Biotech gets Nasdaq bid price notice, has until December 24, 2025
Nektar Therapeutics NKTRRegained complianceNektar Therapeutics regains compliance with Nasdaq minimum bid price rule
SCYNEXIS SCYXDeficiency noticeSCYNEXIS gets Nasdaq minimum bid price notice, has until December 17, 2025 to comply
Bone Biologics BBLGRegained complianceBone Biologics regains compliance with Nasdaq $1.00 minimum bid price rule
Rani Therapeutics Holdings RANIDeficiency noticeRani Therapeutics gets Nasdaq notice over $1.00 minimum bid price
SCYNEXIS SCYXDeficiency noticeSCYNEXIS receives Nasdaq notice for stock below $1.00, has until December 17, 2025
Lipella Pharmaceuticals LIPODelistingLipella Pharmaceuticals CEO says company will seek relisting after Nasdaq delisting
Sutro Biopharma STROReverse splitSutro Biopharma receives Nasdaq notice for falling below $1.00 bid price
Caribou Biosciences CRBURegained complianceCaribou Biosciences regains compliance with Nasdaq $1.00 bid price rule
AIM ImmunoTech AIMDeficiency noticeAIM ImmunoTech gets new NYSE American notice over stockholders' deficit
Annovis Bio ANVSDeficiency noticeNYSE accepts Annovis Bio plan to regain listing compliance
C4 Therapeutics CCCCListing changeC4 Therapeutics holders approve doubling authorized shares to 300,000,000
Vyome Holdings HINDListing changeReShape Lifesciences (now Vyome Holdings) says equity tops Nasdaq $2.5 million minimum
BioNTech BNTXListing changeBioNTech files purchase agreement to acquire CureVac through exchange offer
Equillium EQReverse splitEquillium gets 180 more days from Nasdaq to meet minimum bid price requirement
Incannex Healthcare IXHLListing changeIncannex Healthcare applies to move its listing to the Nasdaq Capital Market
AIM ImmunoTech AIMReverse splitAIM ImmunoTech regains NYSE American compliance as 1-for-100 reverse stock split takes effect
Spruce Biosciences SPRBDeficiency noticeSpruce Biosciences wins Nasdaq panel appeal, with bid price deadline of August 5, 2025
NovaBridge Biosciences NBPRegained complianceI-Mab (now NovaBridge Biosciences) regains Nasdaq minimum bid price compliance
Spruce Biosciences SPRBDeficiency noticeSpruce Biosciences wins Nasdaq appeal, must meet bid price rule by August 5, 2025
Bolt Biotherapeutics BOLTReverse splitBolt Biotherapeutics sets 1-for-20 reverse stock split, trading adjusted June 9
Bolt Biotherapeutics BOLTReverse splitBolt Biotherapeutics effects 1:20 reverse stock split
Tango Therapeutics TNGXListing changeTango Therapeutics holders approve doubling authorized shares to 400,000,000
Talphera TLPHReverse splitTalphera gets second 180-day Nasdaq bid price period, to December 1, 2025
Talphera TLPHReverse splitTalphera gets second 180-day Nasdaq period, until December 1, 2025, to fix bid price
Nektar Therapeutics NKTRReverse splitNektar sets one-for-fifteen reverse split, effective June 8, 2025
Ironwood Pharmaceuticals IRWDDeficiency noticeIronwood Pharmaceuticals gets Nasdaq minimum bid price deficiency notice
Taysha Gene Therapies TSHAListing changeTaysha Gene Therapies holders approve raising authorized shares to 700,000,000
Editas Medicine EDITListing changeEditas Medicine holders approve doubling authorized common stock to 390,000,000
Vyome Holdings HINDDelistingReShape Lifesciences (now Vyome Holdings) sets up $9,700,000 at-the-market program
MetaVia MTVADeficiency noticeMetaVia gets Nasdaq minimum bid price notice, deadline November 25, 2025
CytomX Therapeutics CTMXRegained complianceCytomX Therapeutics regains compliance with Nasdaq minimum bid price requirement
Definium Therapeutics DFTXListing changeMind Medicine (now Definium Therapeutics) grants new CFO inducement awards
Artelo Biosciences ARTLDeficiency noticeArtelo Biosciences gets Nasdaq notice for $652,000 stockholders' equity, below $2,500,000 minimum
Cerenome CNSYDeficiency noticePlus Therapeutics (now Cerenome) gets Nasdaq deficiency notice over late Form 10-Q
Biofrontera BFRIListing changeBiofrontera falls below Nasdaq $2,500,000 stockholders' equity requirement
Q32 Bio QTTBDeficiency noticeQ32 Bio gets Nasdaq notice after reporting stockholders' deficit of ($4.0 million)
Oncopeptides AB ONCODelistingOnconetix gets Nasdaq notice for unfiled 10-Q, issues $294,117.65 note to Keystone
Aptevo Therapeutics APVOReverse splitAptevo Therapeutics gets Nasdaq stockholders' equity notice, sets 1-for-20 reverse stock split
Sol-Gel Technologies SLGLRegained complianceSol-Gel Technologies regains Nasdaq minimum bid price compliance after extension
Petros Pharmaceuticals PTPIDelistingNasdaq panel moves to delist Petros Pharmaceuticals, trading to shift to OTC
Intensity Therapeutics INTSDeficiency noticeIntensity Therapeutics gets Nasdaq stockholders' equity deficiency notice
Dermata Therapeutics DRMARegained complianceDermata regains Nasdaq stockholders' equity compliance but gets bid price delisting notice
Neumora Therapeutics NMRAReverse splitNeumora gets Nasdaq minimum bid price notice, has until November 10, 2025 to comply
Neumora Therapeutics NMRAReverse splitNeumora Therapeutics gets Nasdaq notice for stock below $1.00 bid price
Vyome Holdings HINDReverse splitReShape Lifesciences (now Vyome Holdings) files NT 10-Q, delaying its first-quarter 10-Q
Vyome Holdings HINDReverse splitReShape Lifesciences (now Vyome Holdings) delays first-quarter 10-Q
Valion Bio VBIOListing changeTivic Health (now Valion Bio) ends quarter with $669,000 cash, lines up financing
Sangamo Therapeutics SGMOQListing changeSangamo Therapeutics prices $23.0 million offering of stock and warrants at $0.50
Hepion Pharmaceuticals HEPADelistingNasdaq panel delists Hepion Pharmaceuticals; company expects OTC quotation
Immunome IMNMListing changeImmunome reports $317.3 million in cash and expects runway into 2027
Cosmos Health COSMListing changeCosmos Health gets second 180-day Nasdaq period to lift stock above $1.00
TransCode Therapeutics RNAZReverse splitTransCode Therapeutics faces Nasdaq delisting with no grace period, plans hearing
Palisade Bio PALIDeficiency noticePalisade Bio gets Nasdaq minimum bid price deficiency notice, has 180 days to regain compliance
Palisade Bio PALIDeficiency noticePalisade Bio gets Nasdaq notice for trading below $1.00 minimum bid price
Armata Pharmaceuticals ARMPListing changeArmata Pharmaceuticals flags going concern paragraph, gets $4.65 million from DoD
ABVC BioPharma ABVCDeficiency noticeABVC BioPharma gets Nasdaq equity notice and sells 724,372 shares offshore
Quoin Pharmaceuticals QNRXRegained complianceQuoin Pharmaceuticals regains compliance with Nasdaq $1.00 minimum bid price rule
Scilex Holding SCLXRegained complianceScilex Holding regains compliance with Nasdaq minimum bid price rule
XTL Biopharmaceuticals XTLBDelistingXTL Biopharmaceuticals 20-F lists going-concern and delisting risks
Amarin Corporation AMRNRegained complianceAmarin regains compliance with Nasdaq minimum bid price requirement
Tempest Therapeutics TPSTRegained complianceTempest Therapeutics regains compliance with Nasdaq $1.00 bid price rule
Decoy Therapeutics DCOYReverse splitSalarius Pharmaceuticals (now Decoy Therapeutics) gets Nasdaq delisting notice, plans appeal
Incannex Healthcare IXHLDeficiency noticeIncannex Healthcare Inc. gets Nasdaq minimum bid price notice, has until October 20, 2025
Spruce Biosciences SPRBDelistingSpruce Biosciences gets Nasdaq delisting notice, suspension set for April 29, cuts staff 55%
AEON Biopharma AEONListing changeNYSE American accepts AEON Biopharma plan, sets August 3, 2026 deadline
Aspire-Lakewood Holdings ASBPDeficiency noticeAspire Biopharma (now Aspire-Lakewood Holdings) gets two Nasdaq deficiency letters
Tenaya Therapeutics TNYADeficiency noticeTenaya Therapeutics gets Nasdaq notice for trading below $1.00
PRF Technologies PRFXDelistingPainReform (now PRF Technologies) says Nasdaq found it compliant with Rule 5550(b)(1)
Aspira Women's Health AWHLDelistingNasdaq panel delists Aspira Women's Health over $2.5 million equity rule
LeonaBio LONAReverse splitAthira Pharma (now LeonaBio) wins Nasdaq Capital Market move and 180 more days
Tvardi Therapeutics TVRDReverse splitCara Therapeutics (now Tvardi Therapeutics) closes merger with Tvardi, 1-for-3 reverse split
MIRA Pharmaceuticals MIRADeficiency noticeMIRA Pharmaceuticals gets Nasdaq notice on $2.5 million stockholders' equity requirement
Creative Medical Technology Holdings CELZListing changeNasdaq closes Creative Medical Technology clawback policy compliance matter
MIRA Pharmaceuticals MIRADeficiency noticeMIRA Pharmaceuticals gets Nasdaq notice over $2.5 million equity rule
Palatin Technologies PTNDelistingPalatin Technologies gets NYSE American delisting notice, plans to appeal
Amarin Corporation AMRNListing changeAmarin sets 1-for-20 ADS ratio change for April 11 to keep Nasdaq listing
Semnur Pharmaceuticals SMNRDelistingNasdaq moves to delist Denali Capital (now Semnur Pharmaceuticals), the Semnur SPAC
AIM ImmunoTech AIMDelistingAIM ImmunoTech gets NYSE American delisting notice over low stock price
XBiotech XBITListing changeXBiotech tells Nasdaq of audit committee vacancy after director retires
Dogwood Therapeutics DWTXListing changeDogwood Therapeutics says it has regained Nasdaq stockholders' equity compliance
Tvardi Therapeutics TVRDReverse splitCara Therapeutics (now Tvardi Therapeutics) stockholders approve Tvardi merger share issuance
CDT Equity CDTListing changeConduit Pharmaceuticals (now CDT Equity) says it meets Nasdaq equity standard
CNS Pharmaceuticals CNSPRegained complianceCNS Pharmaceuticals regains Nasdaq bid price compliance, faces one-year monitor
Acurx Pharmaceuticals ACXPDeficiency noticeAcurx Pharmaceuticals gets Nasdaq stockholders' equity deficiency notice
Annovis Bio ANVSDeficiency noticeAnnovis Bio gets NYSE continued listing notice, will submit compliance plan within 45 days
Ironwood Pharmaceuticals IRWDDeficiency noticeIronwood Pharmaceuticals gets Nasdaq deficiency notice over late 2024 Form 10-K
Dermata Therapeutics DRMADeficiency noticeDermata Therapeutics gets Nasdaq stockholders' equity deficiency notice, has until May 9, 2025
Jupiter Neurosciences JUNSDeficiency noticeJupiter Neurosciences gets Nasdaq minimum bid price deficiency notice
Q/C Technologies QCLSDeficiency noticeTNF Pharmaceuticals (now Q/C Technologies) gets Nasdaq minimum bid price notice
Q/C Technologies QCLSDeficiency noticeTNF Pharmaceuticals (now Q/C Technologies) gets Nasdaq minimum bid notice
Minerva Neurosciences NERVDeficiency noticeMinerva Neurosciences keeps Nasdaq listing after meeting $500,000 net income rule
Kyntra Bio KYNBDelistingFibroGen (now Kyntra Bio) appeals Nasdaq delisting notice after missing minimum bid price deadline
Avenue Therapeutics ATXIDelistingNasdaq panel delists Avenue Therapeutics; stock moves to OTC on March 19, 2025
Vaccinex VCNXDelistingVaccinex files Form 25 to voluntarily withdraw its stock from Nasdaq
Gelteq GELSListing changeGelteq signs deal to sell up to $12,000,000 of shares to Lincoln Park
Tiziana Life Sciences TLSARegained complianceTiziana Life Sciences regains compliance with Nasdaq minimum bid price rule
Shuttle Pharmaceuticals Holdings SHPHListing changeShuttle Pharma prices $5.75 million underwritten offering at $0.30 per share
Adial Pharmaceuticals ADILDeficiency noticeAdial Pharmaceuticals gets Nasdaq minimum bid price deficiency notice, has until September 1, 2025
Envoy Medical COCHDeficiency noticeEnvoy Medical receives Nasdaq deficiency notice on $35,000,000 market value requirement
iBio IBIODelistingiBio files Form 25 to withdraw its common stock from NYSE American
Curis CRISDeficiency noticeCuris gets Nasdaq deficiency notice on market value of listed securities
CytomX Therapeutics CTMXDeficiency noticeCytomX Therapeutics gets Nasdaq minimum bid price deficiency notice, has until August 25, 2025
Rallybio RLYBDeficiency noticeRallybio gets Nasdaq minimum bid price notice, has until August 25, 2025
Universe Pharmaceuticals UPCDelistingUniverse Pharmaceuticals gets Nasdaq delisting notice over delayed Form 20-F
Atossa Therapeutics ATOSDeficiency noticeAtossa Therapeutics gets Nasdaq minimum bid price deficiency notice, has until August 20, 2025
Pharming Group NV, Egyptian International Pharmaceutical Industries Co. PHARMPHARDelistingPharming lifts its stake in Abliva to 92.70 percent and extends cash offer to March 6
CDT Equity CDTDelistingConduit Pharmaceuticals (now CDT Equity) repays Nirland note as Nasdaq cites more delisting grounds
Citius Pharmaceuticals, Citius Oncology CTXRCTORListing changeCitius Pharmaceuticals reports $1.1 million cash and expects to raise capital
Evaxion EVAXDelistingNasdaq withdraws Evaxion Biotech (now Evaxion A/S) delisting determination
Ovid Therapeutics OVIDDeficiency noticeOvid Therapeutics gets Nasdaq minimum bid price notice, has until August 11, 2025
BriaCell Therapeutics, BriaCell Therapeutics BCTBCTXRegained complianceBriaCell Therapeutics regains compliance with Nasdaq minimum bid price requirement
Genprex GNPXDeficiency noticeGenprex gets Nasdaq minimum bid price deficiency notice, has until August 6, 2025
Mustang Bio, Fortress Biotech MBIOFBIOReverse splitMustang Bio prices $8 million offering at $3.01 with two series of warrants
China SXT Pharmaceuticals SXTCListing changeChina SXT Pharmaceuticals files securities purchase agreement priced at $0.20 per share
Pluri PLURDelistingPluri gets Nasdaq extension to May 24, 2025 to regain stockholders' equity compliance
PolyPid PYPDDelistingPolyPid says $14.5 million private placement restored Nasdaq equity compliance
Gain Therapeutics GANXRegained complianceGain Therapeutics regains compliance with Nasdaq $50 million market value requirement
Evaxion EVAXListing changeEvaxion Biotech (now Evaxion A/S) completes ADS ratio change, like a 1-for-5 split
Matinas Biopharma Holdings MTNBDeficiency noticeMatinas BioPharma gets NYSE American deficiency notice for missing 2024 annual meeting
Incannex Healthcare IXHLDeficiency noticeIncannex gets Nasdaq deficiency notice on $50.0 million market value requirement
Faeth Therapeutics FTHListing changeSensei Biotherapeutics, Inc. (now Faeth Therapeutics, Inc.) gets 180 more days to meet Nasdaq bid price rule
Revelation Biosciences REVBReverse splitNasdaq panel keeps Revelation Biosciences listed on condition of reverse stock split
Ocugen OCGNDeficiency noticeOcugen gets Nasdaq minimum bid price deficiency notice, has until June 30, 2025
Psyence Biomedical PBMListing changePsyence Biomedical agrees to $2.0 million private placement with warrants
Regen Biopharma RGBPDelistingRegen Biopharma files Form 15 for common and Series A preferred stock
Altamira Therapeutics CYTOFReverse splitAltamira Therapeutics moves from Nasdaq to OTCQB after panel decision
Neutra NTRRDelistingNeutra Corp. files Form 15 to end SEC reporting duties
Calidi Biotherapeutics CLDIDeficiency noticeNYSE American files to remove Calidi Biotherapeutics warrants from listing

How this tracker works

We add an event when the company files it with the SEC (usually a Form 8-K, Item 3.01 for exchange notices) or the exchange publishes it. The split ratio and dates are as stated in the filing. Every row links our story, and every story links the filing, court record or release it is based on. Something missing or wrong? Tell the editors.

News, not investment advice. How we work.

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.